This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Daridorexant
Best-in-class dual orexin receptor antagonist for next-day cognition: 8-hour half-life clears before morning, preserves N3/REM sleep…
Aliases (4)
Overview
What is Daridorexant?
Daridorexant (Quviviq) is a dual orexin receptor antagonist (DORA) FDA-approved in 2022 for insomnia. It is the third DORA after suvorexant and lemborexant and has the shortest half-life of the class.
Key Benefits
Improves sleep onset and sleep maintenance with minimal next-day grogginess due to its ~8-hour half-life. Lower dependence and tolerance risk than benzodiazepines or z-drugs. Better suited for those who must wake clear-headed.
Mechanism of Action
Competitively blocks orexin-1 and orexin-2 receptors in the lateral hypothalamus, suppressing the wake-promoting orexin system. Unlike GABAergic hypnotics, it does not broadly sedate but rather de-activates wakefulness drive.
▸Brand options2 known
StatusSchedule IV (US DEA, effective 2022-04-07) | Class B/POM equivalent (EU, approved 2022-04) | Rx-only most jurisdictions
Research Indications
Half-life ~8 hours
deliberately designed to align with a normal sleep window. Suvorexant is 12 hr, lemborexant is 17-19 hr. The 8-hour half-life is daridore…
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
Tryptophan feeds the melatonin pathway (substrate-side), daridorexant lowers wake drive (receptor-side). They work on different mechanisms with non-overlappi…
(already V4): NMDA modulation + glycinergic relaxation. Mechanistically independent. Safe stack.
(already V4): GABA-A PAM at low doses. Theoretically additive but in practice neither produces strong sedation alone — combining is fine.
(already V4): GABA modulation + glutamate downregulation. Compatible.
Phase 1 study (PMID 33205362) shows additive PD impairment (saccadic velocity, body sway, alertness). FDA labeling says don't combine. For the user zero-alco…
(clarithromycin, ketoconazole, itraconazole, ritonavir, nefazodone, grapefruit juice in large quantities): AVOID — daridorexant exposure can rise 4-5×. Label…
(diltiazem, erythromycin, fluconazole, fluvoxamine, verapamil, ciprofloxacin): Maximum 25 mg dose. Don't titrate to 50 mg.
(carbamazepine, phenytoin, rifampin, St. John's wort, efavirenz, apalutamide, enzalutamide): efavirenz alone reduced AUC by 61%. Daridorexant becomes ineffec…
(benzos, Z-drugs, opioids, gabapentinoids, phenibut, GHB): additive sedation and respiratory risk. Don't double-stack hypnotics.
(in V5 plan): not a hard contraindication but conceptually contradictory the same evening — bromantane upregulates dopamine synthesis (wake-supportive), dari…
same calendar day: pharmacokinetically fine (modafinil is mostly cleared by CYP3A4 induction effects but doesn't significantly inhibit), but functionally red…
same evening: mechanistically theta-rhythm modulation; shouldn't dangerous-stack but probably blunts daridorexant's sleep-permitting effect because Selank is…
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Onset~30-60 min to perceptible relaxation; Tmax ~1-2 hr (food delays Tmax modestly but doesn't change AUC meaningfully). Take ~30 min before bed.
- Peak~1-3 hours after dose. The feel is "reduced wakefulness drive," not sedation. Most users describe it as: thoughts slow down, not in a fog way but in a "I do…
Side Effects & Safety 5
Side Effects
- 1Headache — ~5-10% (lower than the 30%+ seen with modafinil). Usually fades within a week.
- 2Somnolence / fatigue next-day — ~6% at 50 mg, ~4% at 25 mg. More likely in the first week. The 2025 Sleep Medicine paper actually showed *less* next-morning sleepiness vs placebo on average — but the individual variability matters.
- 3Dizziness — ~2-3%, mostly first week.
- 4Nausea — uncommon but reported.
- 5Nasopharyngitis — most common TEAE in the 12-month extension (likely incidental, similar rate as placebo).
When to Stop
- Sleep paralysis — rare in trials (1-2 patients per study arm at 25-50 mg). Manifests as inability to move/speak for seconds-to-minutes during sleep-wake transitions. Almost always benign and self-limited but disturbing if you don't know what it is. Watch period: any time on drug; tends to occur in the first weeks.
- Hypnagogic / hypnopompic hallucinations — vivid perceptions on falling asleep or waking. Reported in ~1-2% of trial subjects. Generally not distressing but disqualifying for users prone to anxiety around sleep.
- Cataplexy-like leg weakness — rare, transient (seconds to minutes). Theoretically linked to OX2 blockade in the brainstem REM-atonia circuits (orexin-deficient narcolepsy patients have cataplexy; pharmacologic orexin blockade produces a milder, dose-dependent version in a tiny subset). Triggered (or not) by laughter/surprise. No complex sleep behaviors (sleepwalking, sleep-driving, sleep-eating) reported in trials — a meaningful safety advantage over zolpidem.
- Compromised respiratory function in severe OSA — labeling caution. Mild-moderate OSA was studied and was fine; severe OSA still flagged. Not relevant for users in this archetype but worth noting.
- Suicidal ideation — class warning across all CNS depressants in US labeling; no signal specific to daridorexant.
- Driving impairment next-day at 50 mg — modest, dose-dependent, especially first week. Don't drive in the morning if you feel residual.
- First 2 weeks: parasomnia/sleep paralysis/hallucination watch. Most reports cluster early. If any disturbing parasomnia → stop, don't titrate up.
- First month at 50 mg: next-day function watch. If grogginess persists beyond 2 weeks at 50 mg, drop back to 25 mg.
References
Daridorexant: First Approval (Markham, Drugs 2022)
definitive first-approval review, PK/PD, regulatory history.
View StudyMignot et al., Lancet Neurology 2022 — pivotal phase 3 trials
1,854 patients across 18 countries; co-primary endpoints WASO and LPS.
View StudyMignot et al., CNS Drugs 2022 — 12-month long-term safety extension
804 patients, 40 weeks, no rebound or withdrawal.
View StudyQuviviq US prescribing information (FDA label)
definitive dosing, contraindications, drug interactions.
View StudyBartoli et al., Translational Psychiatry 2025 — DORA NMA
head-to-head efficacy across daridorexant, lemborexant, suvorexant. DAR50 strongest for TST; LEM10 strongest for sleep onset.
View StudySleep architecture pooled analysis (academic.oup.com/sleep, 2024)
N3/REM/spindle preservation, dose-dependent N1 reduction.
View StudyNext-morning sleepiness analysis, Sleep Medicine 2025
daridorexant *decreased* next-morning sleepiness vs placebo.
View StudyDEA Schedule IV placement, Federal Register 2022-04-07
abuse-liability comparable to suvorexant/zolpidem; less drug-liking than zolpidem 30 mg.
View StudyDaridorexant abuse potential preclinical, PMC10714714
rat self-administration, intracranial-self-stimulation: no evidence of abuse-liking signal beyond reference comparators.
View StudyCYP3A4 metabolism characterization, ChemMedChem 2023
89% CYP3A4 dependence; intramolecular rearrangement mechanism.
View StudyDaridorexant + ethanol PK/PD interaction, PMID 33205362
additive PD impairment, modest PK shift; "do not combine" labeling rationale.
View StudyDaridorexant + citalopram PK/PD interaction, J Psychopharmacology 2021
no clinically meaningful interaction.
View StudyReal-world retrospective single-center study, PMC11176093
confirms phase-3 efficacy in routine clinical practice.
View StudyDrugs.com user reviews (n=182, 2024-2026)
5.4/10 average; 40% positive, 43% negative. Polarized response pattern.
View StudySeltorexant Phase 3 announcement, J&J 2024-2025
selective OX2 antagonist for MDD + insomnia comorbid; comparator for class evolution.
View StudyOrexin receptor antagonists for AD prevention, Drugs 2024
speculative long-term cognitive/AD-modifying potential.
View StudyOrexin system + cognition review, npj Biological Timing and Sleep 2025
chronic OX1R blockade animal-data concerns; relevant for healthy-young user calculus.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.